恩替卡韦对肺结核合并乙肝病毒感染患者治疗及总有效率影响分析

Effect of Entecavir on Treatment and Total Effective Rate of Pulmonary Tuberculosis Patients with Hepatitis B Virus Infection

目的:探析恩替卡韦治疗肺结核合并乙肝病毒感染的临床效果。方法:选择我院64例肺结核合并乙肝病毒感染患者,随机均分为A、B两组。A组予以4ER/4HREZ治疗,B组在A组治疗条件下,运用恩替卡韦。比较两组治疗效果及治疗后肺功能有关指标。结果:B组治疗总有效率为96.88%,显著高于A组的75.00%(P<0.05);治疗8周后,B组治疗后总胆红素(TBIL)、谷草转氨酶(AST)、谷丙转氨酶(ALT)水平均优于A组(P<0.05)。结论:恩替卡韦治疗肺结核合并乙肝病毒感染的临床效果较为显著,值得广泛推广。

Objective:To explore the clinical effect of entecavir in the treatment of pulmonary tuberculosis complicated with hepatitis B virus infection.Methods:64 patients with pulmonary tuberculosis complicated with hepatitis B virus infection were randomly divided into A and B groups.Group A was treated with 4ER/4HREZ and group B was treated with entecavir under the condition of group A.The therapeutic effect and pulmonary function indexes were compared between the two groups.Results:The total effective rate of group B was 96.88%,which was significantly higher than that of group A(75.00%,P<0.05).After 8 weeks of treatment,the levels of total bilirubin(TBIL),glutamic oxaloacetic transaminase(AST)and alanine transaminase(ALT)in group B were better than those in group A(P<0.05).Conclusion:Entecavir is effective in the treatment of pulmonary tuberculosis complicated with hepatitis B virus infection and deserves to be widely promoted.